F. Oliviero James's Insider Trades & SAST Disclosures
F. Oliviero James's most recent trade in Checkpoint Therapeutics Inc was a trade of 15,090 COMMON STOCK done at an average price of $4.0 . Disclosure was reported to the exchange on April 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern F. Oliviero James.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 4.04 per share. | 02 Apr 2025 | 15,090 | 3,759,929 (12%) | 0% | 4.0 | 60,964 | COMMON STOCK |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 3.15 per share. | 07 Feb 2025 | 10,331 | 3,775,019 (12%) | 0% | 3.2 | 32,543 | COMMON STOCK |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 3.41 per share. | 07 Feb 2025 | 9,233 | 3,785,350 (12%) | 0% | 3.4 | 31,485 | COMMON STOCK |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 1,500,000 | 3,794,583 (12%) | 4% | 0 | COMMON STOCK (RESTRICTED) | |
| Checkpoint Therapeutics Inc | Oliviero F. James | Director, CEO, President and Director | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Dec 2024 | 900,000 | 2,294,583 (7%) | 2% | 0 | COMMON STOCK | |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 3.87 per share. | 18 Dec 2024 | 602,167 | 3,414,813 (10%) | 1% | 3.9 | 2,330,386 | COMMON STOCK |
| Checkpoint Therapeutics Inc | F. Oliviero James | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 3.38 per share. | 18 Dec 2024 | 220,230 | 3,194,583 (10%) | 0% | 3.4 | 744,377 | COMMON STOCK |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 2,077,700 | 4,016,980 (12%) | 6% | 0 | COMMON STOCK | |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2024 | 37,890 | 1,939,280 (6%) | 0% | 0 | COMMON STOCK | |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 2.05 per share. | 26 Jun 2024 | 24,610 | 1,977,170 (6%) | 0% | 2.1 | 50,451 | COMMON STOCK |
| Nuvectis Pharma Inc | James F. Oliviero | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 57,828 | - | 0 | Common Stock | |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 1,660,000 | 2,001,780 (6%) | 5% | 0 | COMMON STOCK (RESTRICTED) | |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Feb 2024 | 9,056 | 341,780 (1%) | 0% | 0 | COMMON STOCK | |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 2.06 per share. | 28 Feb 2024 | 5,894 | 350,836 (1%) | 0% | 2.1 | 12,142 | COMMON STOCK |
| Checkpoint Therapeutics Inc | Oliviero James F. | Director, CEO, President and Director | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Feb 2024 | 12,950 | 356,730 (1%) | 0% | 0 | COMMON STOCK | |
| Checkpoint Therapeutics Inc | Oliviero F. James | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 2.01 per share. | 01 Feb 2024 | 11,900 | 369,680 (1%) | 0% | 2.0 | 23,919 | COMMON STOCK |
| Checkpoint Therapeutics Inc | F. James Oliviero | Director, CEO, President and Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2023 | 42,000 | 381,580 (1%) | 0% | 0 | Common Stock | |
| Checkpoint Therapeutics Inc | F. James Oliviero | Director, CEO, President and Director | 31 Dec 2023 | 12,510 | 381,580 (1%) | 0% | 0 | Common Stock | ||
| Nuvectis Pharma Inc | James F. Oliviero | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 18,000 | 27,828 | - | 0 | Common Stock | |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 250,000 | 394,090 (1%) | 0% | 0 | COMMON STOCK (RESTRICTED) | |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 15,000 | 149,573 (0%) | 0% | 0 | COMMON STOCK | |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 4.65 per share. | 27 Feb 2023 | 5,548 | 134,573 (0%) | 0% | 4.6 | 25,798 | COMMON STOCK |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 5.00 per share. | 27 Feb 2023 | 5,483 | 144,090 (0%) | 0% | 5 | 27,415 | COMMON STOCK |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 4.77 per share. | 01 Feb 2023 | 10,261 | 182,121 (0%) | 0% | 4.8 | 48,945 | COMMON STOCK |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 6.75 per share. | 10 Jan 2023 | 3,817 | 192,382 (0%) | 0% | 6.7 | 25,761 | COMMON STOCK |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 60,000 | 196,199 (0%) | 0% | 0 | Common Stock | |
| Nuvectis Pharma Inc | James F. Oliviero | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 15,000 | 15,000 | - | - | Stock Options (right to buy) | |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 455,000 | 3,608,210 | - | 0 | COMMON STOCK (RESTRICTED) | |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 3.51 per share. | 04 Feb 2021 | 70,000 | 3,202,000 (10%) | 0% | 3.5 | 245,525 | COMMON STOCK |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Sale of securities on an exchange or to another person at price $ 3.42 per share. | 04 Feb 2021 | 48,790 | 3,153,210 (10%) | 0% | 3.4 | 166,745 | COMMON STOCK |
| Checkpoint Therapeutics Inc | James F. Oliviero | Director, CEO, President and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2021 | 539,000 | 3,272,000 | - | 0 | COMMON STOCK (RESTRICTED) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges